Which chimeric antigen receptor (CAR) T-cell therapies have been approved for the treatment of diffuse large B-cell lymphoma (DLBCL)?

Updated: Dec 17, 2020
  • Author: Sameh Gaballa, MD, MS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


CAR T-cell therapies approved for treatment of DLBCL include axicabtagene ciloleucel and tisagenlecleucel. A third CAR T-cell therapy, lisocabtagene maraleucel, is awaiting approval for this indication.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!